How Many Systems Does Your First Trial Need? A Registry-Derived eClinical Module Map for Small Sponsors (2026)

TL;DR

Takeaway: In 18,064 industry Phase 1 to Phase 2 clinical trials started between 2021 and 2026, the median study has one capability signal beyond the baseline of electronic data capture and a trial master file. Protocol features and site count set the software scope; the study did not measure sponsor headcount or procurement needs. Oversight obligations are the same for integrated suites, point solutions and contract research organization tooling, and selected public observations illustrate record and handover failures without comparing platform architectures.

Three computed findings frame the procurement choice for early-phase biotechnology and medical technology sponsors [1]. Across 18,064 early-phase trials, 18.4% have none of the four capability signals beyond electronic data capture (EDC) and a trial master file (TMF). A plurality of 49.5% have one capability signal, 24.0% signal two, 7.6% signal three, and 0.4% signal four. Phase 1 trials average 0.92 capability signals, whereas Phase 2 trials average 1.76. This four-signal score is a discussion aid. Capabilities can share a product, use appropriate manual workflows or be omitted from registry text; procurement counts require a separate study-specific assessment.

Registry-footprint groups have similar average scores [1]. Small sponsors, defined here as lead sponsors with three or fewer registered studies in the public registry, average 1.26 capability signals against 1.21 for other industry sponsors. The score includes a point for two or more facilities, so its association with site count is partly built in. Single-site studies average 0.72 capability signals, whereas trials operating across 21 or more facilities average 2.08 capability signals and expand multi-country operations to 79.5%.

Accountability stays with the sponsor whoever hosts or selects the stack [2][3][4]. ICH E6(R3), the European Medicines Agency guideline on computerised systems and the FDA's 2024 electronic-systems guidance place ultimate responsibility for trial data with the sponsor and ask for a system inventory, validated interfaces and documented transfer checks. The public enforcement record cites missing audit trails, failed reconciliations and mismatched records at the seams between systems, and sometimes names software; comparative failure rates by brand or architecture remain unknown.

Two baseline record functions and a median of one additional signal

Takeaway: Reliable data capture and essential-record management are baseline functions for a regulated trial; two separate electronic products are not universally mandated. In this cohort, 49.5% of early-phase industry records have one capability signal on top of it. Phase 1 averages 0.92 capability signals and Phase 2 averages 1.76. Registry text is an unvalidated screening signal, not a procurement census.

For this scoping model, data capture and essential-record management are baseline functions. They may be supported by fit-for-purpose electronic, paper or hybrid arrangements according to applicable requirements [1][5]. Beyond these two baseline functions, early-phase trials add capability signals: interactive response technology or randomization and trial supply management (IRT/RTSM), electronic clinical outcome assessments (eCOA), independent review committee workflows (IRC), and clinical trial management systems (CTMS) for multi-site coordination.

The empirical distribution of capability signals across 18,064 industry-sponsored Phase 1, Phase 1/2, and Phase 2 trials initiated between 2021 and 2026 shows how often four selected public features co-occur [1]. Of these trials, 3,317 (18.4%) signal zero capability signals, with none of the four counted features detected; their actual systems are unknown. A plurality of 8,947 trials (49.5%) signal exactly one capability signal. Two capability signals appear in 4,343 trials (24.0%), three appear in 1,381 trials (7.6%), and four appear in 76 trials (0.4%). The mean across all early-phase records is 1.22 capability signals, as a score from zero to four. Adding two baseline functions would produce 3.22 functions under this convention, not 3.22 observed systems.

The following chart illustrates the distribution of capability signals across development phases.

Phase 1 records (n = 9,578) sit at the minimal end: 24.2% signal zero capability signals, 60.9% one, 13.6% two and 1.2% three, a mean of 0.92 [1]. Phase 1/2 records (n = 2,779) show 20.3% with zero, 49.2% with one, 24.4% with two, 5.6% with three and 0.5% with four, a mean of 1.17. Phase 2 records (n = 5,707) shift upward: 7.6% zero, 30.6% one, 41.4% two, 19.4% three and 1.1% four, a mean of 1.76. Two or more capability signals appear in 14.9% of Phase 1, 30.5% of Phase 1/2 and 61.8% of Phase 2 records.

The count depends on what sits inside the EDC contract and what is a separate module. In this analysis the EDC scope covers case report form design, access control, data entry, edit checks, query management and electronic signatures, together with three baseline obligations that every trial carries: adverse event capture, medical coding where needed under the data-management plan, and the hand-off to whoever files expedited safety reports. Randomisation and trial supply becomes a separate module when the registry records a randomised allocation or any masking, two public fields that flag a review of allocation or masking controls. Assessors may be masked while drug kits remain open-label, and randomisation controls can be provided within an appropriate existing workflow [5]. Related questions concerning kit forecasting, buffer stocks, and shipment shelf-life controls are evaluated in RTSM supply planning, which provides the detailed supporting analysis.

The combinations are concentrated [1]. Randomisation alone is the most frequent addition, 4,735 trials. Multi-site coordination alone follows with 3,801, and the bare EDC and TMF floor with 3,317. Randomisation with multi-site coordination accounts for 2,992 trials, and the triad of IRT, eCOA and multi-site CTMS for 1,148. The remaining pairings are smaller: IRT with eCOA (698), eCOA with multi-site CTMS (402), eCOA alone (291), IRC with multi-site CTMS (196), IRT with IRC and CTMS (167), IRC alone (120) and all four modules (76).

The following chart displays the ten most frequent module combinations observed in early-phase clinical development.

Explicit independent central review is rare in these combinations because it is rare in the public text [1]. Central-review language appears in 3.8% of early-phase records (680 trials). Response criteria such as RECIST, iRECIST, RANO, Lugano and IMWG appear in 19.4% (3,512 trials) and are treated here as a candidate need, since a protocol can apply the criteria through investigator assessment and add central review only at a later phase.

Three early-phase profiles to use in scoping

Takeaway: Three broad profiles cover much of this early-phase cohort; first-ever sponsor studies were not separately identified, each with its own registry signature. Healthy-volunteer Phase 1 records are dominated by external data streams, patient dose-escalation Phase 1 records by multi-site coordination, and Phase 2 records by two or three modules at once.

Three broad profiles organise the early-phase industry records, and each carries a characteristic set of public features [1]. Buying beyond the profile adds validation and licence cost for functions the protocol never exercises.

The first archetype is the single-site, healthy-volunteer Phase 1 study [1]. It covers 4,364 trials, 45.6% of all Phase 1 records in the cohort, and is the profile most often run inside a dedicated Phase 1 unit. In these records 73.1% are randomised or masked and 43.8% carry a masking code other than none, consistent with crossover and placebo-controlled ascending-dose designs. Patient-reported outcome terms appear in 3.0%, explicit central review in 0.2% and dose-escalation language in 31.4%.

External data is the dominant integration task for this profile [1]. Pharmacokinetic, laboratory, ECG or biomarker terms appear in 89.8% of these records, which flags possible external streams. Confirm the actual data source, transfer method and systems in the protocol and vendor specifications. On capability signals, 1,143 trials signal none, 3,114 signal one (almost always randomisation), 106 signal two and one signals three. The priority for this profile is a fast database build and validated transfer specifications, and the need for a separate site-management product depends on the actual oversight workflow.

The second archetype is the patient Phase 1 study, with dose-escalation language in a subset [1]. It covers 4,135 trials. Only 22.2% of these records are randomised or masked, while dose-escalation language (3+3 rules, Bayesian optimal interval designs, cohort and dose-level wording) appears in 64.5%.

Patient Phase 1 records are spread across sites [1]: 60.1% list two or more facilities and 24.8% two or more countries. External data terms appear in 73.0%, patient-reported outcome terms in 8.4% and explicit central review in 1.5%. The operational load sits in cohort slot allocation, dose-limiting toxicity tracking, safety-review data cuts and cross-site monitoring, which makes database access, continuity and reconciliation important. Direct licensing, CRO provision and hosting arrangements can each be evaluated against those needs. Structural protocol complexity and schedule-of-activities density are evaluated in protocol complexity and study-build workload, which provides the detailed supporting analysis.

The third archetype is the Phase 2 study, with randomised and multi-site features in subsets [1]. It covers 5,707 trials. Randomisation or masking appears in 71.4% of Phase 2 records, which is the signal for an IRT/RTSM module with stratification and blinded supply. Multi-site deployment appears in 65.9% and multi-country execution in 34.1%.

Outcome instruments arrive in Phase 2 [1]. Patient-reported outcome terms appear in 30.4% of Phase 2 records, explicit central review in 7.9%, response criteria in 16.4% and external data streams in 38.7%. With 61.8% of Phase 2 records signalling two or more capability signals, this is the profile where the number of interfaces, and the reconciliation work between them, becomes the procurement question.

Small registry footprints do not imply low scores

Takeaway: Sponsors with a small registry footprint show the same module signals as other industry sponsors: 1.26 capability signals on average against 1.21. The differences are in patient-reported terms and country count, and both point to the protocol, not the company.

Testing whether small companies run simpler trials needs a public proxy for size [1]. In this analysis a small sponsor is a lead sponsor with three or fewer registered studies in the registry across all study types and years. The proxy measures registry footprint rather than headcount or funding, with affiliates, aliases and incomplete registration limiting its usefulness for identifying first-time companies.

Within the cohort of 18,064 early-phase industry trials, 3,253 studies were initiated by small sponsors, while 14,811 were initiated by larger industry sponsors [1]. Small sponsors average 1.26 capability signals per protocol, while larger sponsors average 1.21. The module-count distributions are close: small sponsors show 14.7% with zero modules, 53.2% with one, 24.0% with two, 7.9% with three, and 0.2% with four. Larger sponsors show 19.2% with zero modules, 48.7% with one, 24.1% with two, 7.6% with three, and 0.5% with four.

The following chart compares the feature rates of small sponsors against other industry developers.

Module by module the differences are small [1]. Randomisation or masking appears in 52.2% of small-sponsor records and 55.2% of other industry records; two or more facilities in 50.8% against 48.5%. Small sponsors show patient-reported outcome terms more often (20.4% against 13.7%). The registry gives no reason for that gap; a candidate explanation is the mix of indications in first programmes, and it should be read as a prompt to check the instrument list rather than as a rule.

Other industry sponsors run more multi-country trials [1]: 23.1% list two or more countries against 16.9% for small sponsors. Explicit central review appears in 4.1% against 2.4%, and external data terms in 66.3% against 58.8%, a difference that may relate to the higher share of healthy-volunteer Phase 1 records among large sponsors (35.6% against 26.9%).

Similar descriptive means appear under the tested registry-footprint thresholds [1]. Restricting small sponsors to those with a single registered study yields a mean of 1.23 capability signals across 1,273 trials. Defining small sponsors as those with five or fewer studies yields a mean of 1.26 modules across 4,641 trials. A threshold of ten or fewer studies yields 1.25 modules across 6,982 trials. Restricting the threshold to sponsors with three or fewer industry trials initiated within the 2021 to 2026 window yields 1.29 modules across 4,587 trials. Large developers with more than 50 registered studies average 1.25 modules across 7,207 trials.

The phase split says the same [1]. In Phase 1, small-sponsor trials average 0.99 capability signals compared to 0.90 for larger developers. In Phase 1/2, small sponsors average 1.18 modules compared to 1.16. In Phase 2, small sponsors average 1.82 modules compared to 1.75. The proportion of records signalling two or more capability signals among small sponsors rises from 16.5% in Phase 1, to 28.7% in Phase 1/2, and to 64.4% in Phase 2. A first-trial protocol carries the modules its design implies, whatever the size of the company behind it.

Site count and the score partly overlap by design

Takeaway: The score includes a point for two or more facilities, so its association with site count is partly built in. Single-site records average 0.72 capability signals; records with 21 or more facilities average 2.08, and 79.5% of them span two or more countries.

In this cohort the score increases across facility bands, partly because the score itself contains a multi-site flag. This is not independent proof that site count predicts software needs [1]. As a trial grows from one unit to dozens of centres, the coordination, oversight and data-flow surface grows with it.

Four facility bands make the relationship visible [1]. Single-site records number 9,224: 36.0% signal zero capability signals, 55.8% one, 8.2% two and 0.1% three, a mean of 0.72, with no multi-country records by construction.

Trials operating across 2 to 5 facilities encompass 3,145 studies [1]. In this band, mean capability signals increase to 1.58. Multi-country distribution appears in 17.1% of trials. The intermediate band of 6 to 20 facilities contains 3,254 studies, averaging 1.64 capability signals, with 46.0% operating across multiple countries.

Records with 21 or more facilities number 2,441 [1]. None signals zero capability signals; 24.1% signal one, 45.3% two, 28.7% three and 1.9% four, a mean of 2.08, and 79.5% list two or more countries.

The following chart illustrates how module need rates shift across investigative facility bands.

The modules scale at different rates [1]. Patient-reported outcome terms appear in 10.9% of single-site trials, 13.5% of trials with 2 to 5 sites, 17.1% of trials with 6 to 20 sites, and 28.7% of trials with 21 or more sites. Explicit independent central review language increases from 2.0% in single-site studies, to 2.6% in 2 to 5 site studies, to 4.3% in 6 to 20 site studies, and to 11.3% in studies with 21 or more sites. Response-criteria language rises from 11.7% in single-site records to 30.1% in the largest band.

Randomisation follows a U shape [1]: 59.5% of single-site records, 42.0% in the 2 to 5 band, 42.7% in the 6 to 20 band and 68.5% in the 21-plus band. The single-site peak is consistent with healthy-volunteer designs (73.1% of single-site healthy-volunteer Phase 1 records are randomised or masked); the 21-plus peak is where randomisation meets stratification and supply across depots. Both ends call for a review of allocation or masking controls. Supply-system scope depends on the actual product, kit, depot and resupply design, which these fields do not establish.

Small sponsors in the largest band look like everyone else in it [1]. Among 198 small-sponsor records with 21 or more facilities, none signals zero capability signals, 21.7% signal one, 46.0% two, 31.8% three and 0.5% four; randomisation appears in 73.2%, patient-reported terms in 29.3%, explicit central review in 8.6% and multi-country in 73.7%. Across the whole cohort, facilities have a median of 1, a 75th percentile of 9, a 90th percentile of 28 and a maximum of 456; countries have a median of 1, a 90th percentile of 5 and a maximum of 37.

What the registry cannot tell you

Takeaway: The registry records endpoints and facilities, and is silent on three layers that carry most of the integration work: external data streams, the safety database, and central review that the protocol describes without naming.

The registry records design, population and outcomes, and stays silent on system architecture, vendor delegation and data integration [1]. Three of the silences matter for scoping.

The first is external data [1]. Across the cohort, 65.0% of records name pharmacokinetic, laboratory, ECG, biomarker or immunogenicity endpoints, and 81.7% of Phase 1 records do. None of these streams is a module in the count, yet each may require a transfer between systems or controlled direct capture, which ICH E6(R3) section 4.2.5 expects to run through validated processes or reconciliation so that data and metadata keep their integrity [2].

The second is the safety database [1]. The registry records whether a data monitoring committee exists (27.6% of the cohort) and nothing about where serious adverse events are held or how they reach the authorities. Reconciling serious adverse events between the clinical database and the pharmacovigilance database is described in the literature as a time-consuming and imprecise task, and it sits entirely outside the registry [6].

The third is central review [1]. Explicit central-review phrases appear in 3.8% of records (680), while response criteria appear in 19.4% (3,512). The gap is consistent with investigator assessment against the criteria in early phase, with central reading added later, but the registry cannot confirm that for any single trial. Where the protocol does depend on a central read, image transfer, de-identification, reader assignment and adjudication records become a workflow of their own.

Where fragmented stacks fail: the inspection record

Takeaway: The public inspection record places data-integrity failures at the interfaces between systems, vendors and sites. Form 483 frequencies keep the sponsor-oversight cluster visible every year, and the warning letters that name a system describe source that disagrees with the EDC, a supplier that closed its EDC, and a vendor that deleted data with its audit trails.

Two FDA files describe what inspectors cite [7][8]. Read together, they rarely name a computerised system and repeatedly describe the seams where systems, vendors and sites meet.

The Form FDA 483 workbooks for the Bioresearch Monitoring (BIMO) programme cover fiscal years 2006 to 2025 [7]. Each row is a citation frequency sum, the number of times a reference was cited in a year; the file carries no inspection denominator, so these are counts of citations and never rates of failure. Across all evaluated years, investigator protocol adherence under 21 CFR 312.60 accounts for 2,781 citations. Investigator case history maintenance under 21 CFR 312.62(b) accounts for 1,602 citations. Institutional Review Board compliance under 21 CFR Part 56 accounts for 2,907 citations, while informed consent under 21 CFR Part 50 accounts for 1,076 citations. Good Laboratory Practice citations under 21 CFR Part 58 total 1,410.

The sponsor cluster, based on the selected sponsor-responsibility references on the BIMO sheets, sums to 631 citations [7]. It covers investigator selection, monitoring, ensuring compliance with the plan and protocol, shipment records and the transfer of obligations to a contract research organisation. Within it, 21 CFR 312.50 (general responsibilities of sponsors, including ensuring compliance with the plan and protocol) sums to 283 citations across three workbook labels (156, 83 and 44). Obtaining the Form FDA 1572 investigator statement under 21 CFR 312.53(c)(1) sums to 57. Failing to address investigator non-compliance under 21 CFR 312.56(b) accounts for 30 citations. Maintaining shipment and disposition records under 21 CFR 312.57(a) accounts for 24 citations, and failing to execute monitoring under 21 CFR 312.56(a) accounts for 19 citations.

The following chart tracks Form FDA 483 citation frequency sums across primary BIMO inspection themes from FY2015 through FY2025.

The sponsor cluster persists at a low level [7]. Annual sums were 29 in FY2015, 41 in FY2016, 31 in FY2017, 23 in FY2018, 28 in FY2019, 17 in FY2020, 7 in FY2021, 10 in FY2022, 19 in FY2023, 29 in FY2024, and 15 in FY2025. Investigator case-history citations ran higher throughout, 59 in FY2024 and 57 in FY2025. Investigational product accountability under 21 CFR 312.62(a) totaled 535 citations across all years, recording 6 in FY2024 and 11 in FY2025. Broader trends in 21 CFR Part 11 enforcement and computerized system inspection metrics are examined in computerized-system inspection signals, which provides the broader inspection context.

The warning-letter file supplies selected examples [8]. Of 3,643 letters issued from 2021 to July 2026, 69 carry a clinical-investigator, sponsor, BIMO, IRB or bioequivalence subject. In those 69, 10 mention a contract research organisation or transfer of obligations, 10 cite monitoring, 9 cite case histories, 7 name an EDC or eCRF, 5 cite product accountability, and 11 contain seam language: transcription, reconciliation, audit-trail loss, or a discrepancy between source and an electronic system.

Five passages, quoted as FDA wrote them, show the mechanism:

March 2026, clinical investigator [9]: "At times, source data did not match information in the Electronic Data Capture (EDC) system, source records were missing, and data entries (including late entries) in source documents and the EDC system were nonattributable, with no documentation or explanation for the changes and/or discrepancies."

March 2025, Bioresearch Monitoring Program [10]: "You state that this occurred because the company supplying the investigational product for this study, (b)(4), closed its Electronic Data Capture (EDC) system."

December 2024, sponsor [11]: "...a third-party vendor contracted by Applied Therapeutics deleted electronic data in Q-global®, including associated audit trails, for the (b)(4) for all 47 subjects enrolled in the study at all (b)(4) clinical sites."

October 2024, clinical investigator [12]: "Multiple discrepancies were observed between the sponsor forms, progress notes, and electronic data capture (EDC) regarding the time at which these activities were performed for at least nine subjects."

May 2024, clinical investigator [13]: "...your site performed a comprehensive investigation, including but not limited to a complete accountability and reconciliation of all available kits onsite and in the Interactive Web Response System (IWRS); however, the exact cause remains unknown."

The selected passages illustrate different record-continuity and reconciliation problems: a record in one place disagrees with, or disappears from, a record in another. Manual transcription between medical records and eCRF, a supplier closing its EDC, a vendor deleting data with its audit trails, and kit counts that diverge from the IWRS are all seams. Actual interface counts depend on topology, data streams and manual handoffs, with each actual connection counted separately. Their selection and lack of an architecture comparator leave causes and suite-versus-point-solution outcomes unresolved. Registry counts and letter counts are independent evidence, and the letters are few; they illustrate possible failure modes, not their incidence or an architecture effect.

What the rules require of any stack, one system or five

Takeaway: ICH E6(R3), the EMA computerised-systems guideline and the FDA electronic-systems guidance ask the same things of a sponsor with one system or five: a system inventory with interfaces, validated trial-specific configuration and transfers, a data-flow diagram, and documented oversight of service providers.

Delegating operations to a CRO or buying cloud software moves work, and ICH E6(R3), adopted in two stages in January 2025 and June 2026, is explicit about where responsibility stays [2]. Section 3.6.4 states that "The sponsor's trial-related activities that are not specifically transferred to and assumed by a service provider are retained by the sponsor." Section 3.6.6 reinforces that "the ultimate responsibility for the sponsor's trial-related activities ... resides with the sponsor." Section 3.6.7 adds that the sponsor "is responsible for assessing the suitability of and selecting the service provider." Section 3.6.9 extends that oversight to activities the service provider subcontracts.

Oversight is meant to scale with the trial [2]. ICH E6(R3) Section 3.9.5 specifies that "The range and extent of oversight measures should be fit for purpose and tailored to the complexity of and risks associated with the trial. The selection and oversight of investigators and service providers are fundamental features of the oversight process." Under Principle 9.3, "Computerised systems used in clinical trials should be fit for purpose (e.g., through risk-based validation, if appropriate)." Section 3.16.1(d) further states that data acquisition tools should be fit for purpose, validated, and ready before use.

Validation reaches past the product into the trial's own configuration and its connections [2]. ICH E6(R3) Section 4.3.4(e) states that "Both standard system functionality and protocol-specific configurations and customisations ... should be validated. Interfaces between systems should also be defined and validated. Different degrees of validation may be needed for bespoke systems, systems designed to be configured or systems where no alterations are needed." Section 4.3.4(a) bases the validation approach on a risk assessment of intended use, the importance of the data and the potential effect on participants and results.

Transfers get their own clause [2]. ICH E6(R3) Section 4.2.5 states that "Validated processes and/or other appropriate processes such as reconciliation should be in place to ensure that electronic data, including relevant metadata, transferred between computerised systems retains its integrity." Section 4.2.6(b) lists reconciliation of relevant databases among the activities that finalise data sets before analysis. Section 3.16.1(c) says that where necessary a data flow diagram should be contained in a protocol-related document such as a data management plan, and section 4.2.1(a) ties the extent of verification of manually transcribed data to the criticality of the data.

The EMA guideline is built around the same seams [3]. The Guideline on computerised systems and electronic data in clinical trials (EMA/INS/GCP/112288/2023), adopted 7 March 2023, covers computerised systems "including instruments, software and 'as a service'" and states that its references to sponsors and investigators also apply to their service providers. Section 4.2 describes sponsors operating systems directly or "via service providers, including organisations providing e.g. eCOA, eCRF, or IRT." On accuracy it states that "The process of data transfer between systems should be validated."

It then names the artefacts [3]. Section 5.1: "Where multiple computerised systems/databases are used, a clear overview should be available ... System interfaces should be described." Section 4.10 asks for validation of the trial-specific configuration, giving "eligibility criteria questions in an eCRF, randomisation strata and dose calculations in an IRT system" as examples. Section 6.1.2 on transfer adds that "All transfers that are needed during the conduct of a clinical trial need to be pre-specified," and the guideline encourages a data management plan that describes what is transferred, in what format, from where to where and with what reconciliation.

The FDA's October 2024 guidance reads the same way [4]. In Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers (Revision 1), Section B states that electronic systems used for randomization, data collection, adverse event processing, consent, records, and product accountability should be "fit for purpose and implemented in a way that is proportionate to the risks." Question 7 clarifies that validation expectations apply to "configurations specific to the clinical trial protocol, customizations, data transfers, and interfaces between systems."

Question 8 names the document a sponsor should be able to produce [4]: for each investigation, the electronic systems used (the guidance lists EDC, clinical trial management, interactive response technology and electronic clinical outcome assessment as examples) and the system requirements, including "a diagram that depicts the flow of data from data creation to final storage." Section C states that regulated entities remain responsible for records held by IT service providers and lists what to assess in a provider: oversight policies, validation processes, the ability to produce complete copies and retain records, migration and backup procedures, access controls, audit trails and protection of data in transit and at rest.

Two older FDA documents fix the ends of the data flow [14][15][16]. The 2013 guidance on electronic source data states that direct entry into the eCRF "can eliminate errors by not using a paper transcription step" and sets out the aim of eliminating unnecessary duplication of data [14]. At the submission end, the Standardized Study Data guidance (Revision 2, June 2021), issued under section 745A(a) of the Federal Food, Drug, and Cosmetic Act, states that standardized study data are required for NDAs, ANDAs and certain BLAs for studies that started after 18 December 2016, and for certain INDs for studies that started after 18 December 2017, in the formats listed in the FDA Data Standards Catalog; conformance is assessed on the demographics dataset, the subject-level analysis dataset and the define.xml file [15][16].

Between those ends, the interoperability contracts are published standards rather than vendor promises [17][18][19][20]. CDISC describes ODM as "a vendor-neutral, platform-independent data exchange format, intended primarily for interchange and archival of clinical study data," carrying clinical data with its metadata, administrative data and audit information; ODM v2.0 adds a REST API specification and a JSON media type [17]. Define-XML "transmits metadata that describes any tabular dataset structure," is used for dataset metadata in applicable FDA and PMDA standardized-data submissions; exact scope and accepted versions depend on the submission requirements, and reached v2.1.11 on 6 April 2026 [18]. The TMF Reference Model, part of CDISC since June 2022 and at version 3.3.1, gives the trial master file a standard taxonomy that survives a change of eTMF vendor [19]. TransCelerate's eSource initiative, begun in 2016 and now completed, produced among other things a mapping between HL7 FHIR and SDTM for laboratory results, adverse events and the schedule of activities [20].

Put together, the deliverables are the same for a single suite, five point solutions or a CRO-supplied stack [2][3][4]: a system inventory with interface descriptions, a data-flow diagram from creation to archive, validation evidence for the protocol-specific configuration, a validated or reconciled process for every transfer, and documented selection and oversight of each service provider. The sourcing choice decides how many of each there are.

The module map

Takeaway: Read the synopsis left to right: each observable feature flags a capability to assess, the registry rate says how common that feature is in trials like yours, and the last column says what to confirm in the protocol before it becomes a line in a contract.

The map ties each module to a feature that is visible in a synopsis, gives its rate across the 18,064 early-phase industry records, and names the protocol detail that decides whether the row applies [1]. The rate describes the cohort; the protocol and applicable requirements determine the implementation.

The following table presents the scoped eClinical capability map for early-phase clinical development.

The first row is the floor [1]. Before signing anything, settle who owns the database, in what format it exports, and what the first data-flow diagram looks like.

Randomised allocation or any masking activates the second row [1]: 54.7% of the cohort, 50.7% of Phase 1 and 71.4% of Phase 2. What turns it into a supply system rather than a list is in the protocol: strata, block size, emergency unblinding, packaging, expiry and resupply. The RTSM supply planning article works through those flags and is not repeated here.

Dose-escalation language activates the third row [1]: 39.7% of the cohort, 46.5% of Phase 1 and 15.9% of Phase 2, and 59.0% of those records are non-randomised. The decision is where slot allocation and dose assignment are controlled, in the IRT or in an EDC workflow, and how the safety-review data cut is produced.

Patient-reported and clinician-rated instruments activate the fourth and fifth rows [1]. Patient-reported terms appear in 14.9% of the cohort, 5.6% of Phase 1 and 30.4% of Phase 2; clinician-rated scales in 10.3%, 5.0% and 20.4%. The protocol details that matter are the instrument licence and version, languages, device strategy and, for rated scales, the rater roster and its training evidence.

The sixth and seventh rows keep explicit central review (3.8%; 0.7% of Phase 1, 7.9% of Phase 2) apart from response-criteria language (19.4%; 15.5% and 16.4%) [1]. The question for the protocol is whether any endpoint depends on a central read now or at the next phase, because the charter, reader assignment and adjudication record are a workflow that is easier to start than to retrofit.

External data activates the eighth row in 65.0% of the cohort, 81.7% of Phase 1 and 38.7% of Phase 2 [1]. Each stream needs a transfer specification, a format, a cadence and a named reconciliation owner, which is the content of the data-flow diagram the guidance asks for.

Two or more facilities activate the ninth row (48.9%; 34.9% of Phase 1, 65.9% of Phase 2) and two or more countries the tenth (22.0%; 12.6% and 34.1%) [1]. The first adds site activation, monitoring and payment tracking; the second adds country-level submissions, languages and essential documents to the trial master file.

The last two rows are edge cases [1]. Decentralised or digital health technology language appears in 1.2% of records, now within the scope of ICH E6(R3) Annex 2. The single-site healthy-volunteer Phase 1 row, 45.6% of Phase 1 records, is where a unit's own EDC and randomisation system is a reasonable default, provided database ownership, audit-trail access and export rights are written into the agreement.

Suite, best-of-breed or CRO-supplied: the sourcing decision path

Takeaway: The sourcing model decides where the seams sit: inside one vendor's architecture, between vendors, or in the CRO contract and the final export. It never removes them, and the literature on transcription error, EHR-to-EDC transfer and safety reconciliation says where each seam costs the most.

Three sourcing models are on the table for a first trial: an integrated suite from one vendor, a best-of-breed set of point solutions, or the stack the contract research organisation already runs.

The decision path below links each trial profile to a defensible default, the seams the sponsor keeps, and the question to ask before signing [1][2][3][4].

The following table delineates the sourcing decision path across standard clinical development archetypes.

For a single-site healthy-volunteer Phase 1 study with zero or one capability signal, the unit's own EDC and randomisation tools are a defensible default [1]. An established unit may already have suitable systems and trained staff; confirm that evidence rather than assuming either reuse or duplication. The seam moves to the agreement: written transfer of obligations, database ownership, audit-trail access after close-out, and an export in a standard structure.

For a patient Phase 1 dose-escalation study across several centres, the default shifts to a sponsor-held EDC that the CRO operates, with a transfer specification for each external stream [1]. External data terms appear in 73.0% of patient Phase 1 records, so the interfaces are the main task, and holding the database means the structure carries into the Phase 2 expansion.

For a randomised multi-site Phase 2 study with patient-reported outcomes, two or three separately sourced capabilities may introduce interfaces, whose actual number and risk must be mapped, and under ICH E6(R3) section 4.3.4(e) and EMA section 5.1 each interface is an object to describe and validate [1][2][3]. An integrated suite, or a best-of-breed set whose interfaces already carry validation evidence, is the defensible default here.

The literature measures selected data-processing tasks, rather than software procurement cost. Garza and colleagues pooled 93 papers published between 1978 and 2008 on data-processing error rates in clinical research [21]. Medical record abstraction carried a pooled error rate of 6.57% (95% CI 5.51 to 7.72), optical scanning 0.74%, single data entry 0.29% and double data entry 0.14%. The papers cover older methods and heterogeneous settings. Their results support assessing each processing step in context. FDA’s 2013 eSource guidance addresses reducing avoidable transcription, while a current platform’s accuracy needs its own evidence.

On the oversight side, Williamson and colleagues' single-company case study at Faron Pharmaceuticals opens with the observation that many small pharmaceutical companies "lack the resources, knowledge and expertise of the regulatory landscape for adequate vendor management" [22]. Their conclusion is modest and useful: quality tolerance limits, key performance indicators, standard operating procedures and communication plans were sufficient oversight mechanisms for one small company. The wider literature on small-sponsor operations is thin; a live search returned 165 records, most of them off topic [23].

The EHR-to-EDC studies show what automation of one seam currently delivers [24][25][26]. In the TransFAIR comparison across six European trials, 6,143 data points were transferred accurately, 39.6% of the in-scope data and 16.9% of all data, with laboratory results making up 65.4% of what moved; the authors point to harmonisation of data standards as the next constraint [24].

Pfeffer and colleagues, across multiple phase I cancer trials, moved 11,342 data points in 15 months, 89% of them laboratory values, at an average of 37 seconds per case report form, and name variability in EHR standards as the practical barrier [25]. Cheng and colleagues measured the set-up cost of scaling automated entry to two further sites at about 26 and 15 hours, and estimated that for 20 participants automation could have prevented 764 of the errors that persisted after monitoring in 4,404 human-entered fields and saved 17 hours [26]. These are single-network evaluations; they show feasibility and the shape of the cost, not a general saving.

The safety seam has its own measurement. Contu and colleagues describe reconciliation of serious adverse events between the clinical database and the pharmacovigilance database as a task that "remains a very time-consuming and imprecise task," and their tool matched the same event across the two databases correctly in 97.2% of 13 reconciliation files holding 290 events, six times faster than senior data managers working by hand [6]. Site readiness is the other constraint: in a survey of 61 respondents at paediatric trial sites, only 21% of sites exchanged patient data with other institutions using FHIR, and the authors conclude that readiness "is not merely a technical problem" [27].

Publicly funded research points the same way [28]. In a 31-phrase eClinical corpus of 4,876 NIH project applications, integration and interoperability language rose from 8.6% of applications in FY2015 to FY2019 to 11.1% in FY2024 to FY2026, and data-standards language (CDISC, ODM, SDTM, common data models) from 1.9% to 3.8%. Single or unified platform language stayed below 1% throughout. An application is a research theme, not adoption or product evidence; it shows selected theme frequencies within a keyword-defined funded-research corpus, not the full distribution of funded problems.

The following chart illustrates the longitudinal trajectory of integration, data standards, and unified platform themes in federal eClinical research projects.

The literature counts agree [23]. A fixed Europe PMC query for electronic data capture with integration, interoperability, data transfer or reconciliation returns 85 records for 2015, 191 for 2019, 616 for 2023 and 1,243 for 2025; a reconciliation and transcription-error query returns 63 for 2015 and 250 for 2025; an eSource and EHR-to-EDC query returns 15 for 2015 and 36 for 2024. These are search-hit counts and grow with the literature as a whole, so they are context, not a trend claim.

For a small sponsor the arithmetic is simple [2][3][22]. Four or five point solutions mean four or five agreements, access models and audit trails, and ICH E6(R3) asks that each interface between them be defined and validated; a company that already lacks vendor-management capacity multiplies the thing it is short of.

EClinCloud is one example of the integrated option: its platform includes EDC, RTSM, CTMS, eTMF, eCOA and IRC, its EDC page describes native connections to RTSM, eCOA and CTMS with integration scope confirmed during evaluation, and its services cover study build, configuration and managed operations [29][30][31]. An integrated platform can reduce the number of cross-vendor interfaces a sponsor has to inventory and validate. It leaves the inventory, the validation of the trial-specific configuration, the transfer specifications for external streams and the oversight of the provider exactly where the guidance puts them, with the sponsor.

Define the deliverables behind "SDTM-ready"

Takeaway: An EDC export starts the mapping and conformance work needed for an SDTM package. Readiness is a property of the CRF design, the metadata, the external-data mappings and the conformance checks, and five questions to a vendor or CRO reveal which of those they actually own.

When a proposal uses "SDTM-ready", ask what deliverables that phrase covers. An EDC holds the collected data and its metadata; the submission package is the tabulation datasets, the analysis datasets and a define.xml that describes them, and getting from one to the other is a mapping and conformance process that someone has to own [15][17][18].

The requirement is real and dated [15][16]. Standardized study data are required in NDAs, ANDAs and certain BLAs for studies started after 18 December 2016 and in certain INDs for studies started after 18 December 2017, in the formats the Data Standards Catalog lists, and FDA assesses conformance on the demographics dataset, the subject-level analysis dataset and define.xml, with published Technical Rejection Criteria and a Conformance Guide. A 2026 start meets the timing condition, but the requirement also depends on submission type and regulatory scope; certain non-commercial INDs and other exclusions or waivers must be assessed.

Readiness therefore starts at CRF design and runs through every external stream [15][18]. CDISC-aligned terminology can help mapping with conformance established through mapping and validation; laboratory, bioanalytical and imaging files that arrive in their own formats need a documented transformation; and define.xml needs a mapping specification that connects each collected field to its submission variable.

Five questions separate an export from a package [4][15][17][18]:

First, what exact CDISC ODM version does the EDC system export natively, and does the export include operational audit trails and item-level metadata [17]?

Second, are standardized SDTM variable annotations generated automatically from the CRF design specifications, or do annotations require manual post-hoc document programming?

Third, what validated process ingests, formats and maps external laboratory and pharmacokinetic streams into their SDTM domains?

Fourth, is define.xml generated from the study metadata, or programmed afterwards by a third party [18]?

Fifth, which conformance checks against the current Data Standards Catalog and Technical Rejection Criteria run before database lock, and who sees the output [15][16]?

Frequently asked questions

Takeaway: Four questions that reach this topic as search queries, answered from the evidence above.

For a 20-person biotechnology sponsor starting its first Phase 1 trial, what software is necessary?

Electronic data capture and a trial master file, then whatever the protocol adds [1]. For a single-site healthy-volunteer study, 89.8% of comparable registry records name pharmacokinetic, laboratory or ECG endpoints and 73.1% are randomised or masked, so the work is external data transfer and allocation control, and the unit's own EDC and randomisation system is a reasonable default if ownership, audit-trail access and export are in the agreement. For a multi-site patient dose-escalation study, plan a sponsor-held EDC with cohort management and a transfer specification per external stream. Defer CTMS, eCOA and central review until a protocol feature calls for them.

Should the contract research organization choose the eClinical tools?

The CRO can propose and operate the tools; the selection and its oversight stay with the sponsor [2][4]. ICH E6(R3) section 3.6.7 makes the sponsor responsible for assessing and selecting the service provider, and the FDA guidance keeps regulated entities responsible for records held by IT service providers. Ask for the validation summary and the evidence for the trial-specific configuration, and put database ownership and audit-trail access at close-out in the contract.

Should a sponsor choose an all-in-one integrated suite or a best-of-breed software stack?

Count the modules the protocol implies [1][2]. A zero-or-one score can still conceal many laboratory, safety, archive and manual interfaces. With two or three, as in most Phase 2 records, separately sourced modules can add interfaces that ICH E6(R3) section 4.3.4(e) expects to be defined and validated, and a suite or a set with established interfaces may simplify management. Verify the actual inventory and trial-specific validation scope. Neither option removes the inventory, the data-flow diagram or the provider oversight.

What eClinical systems should a mid-size contract research organization standardise on?

A core platform for EDC, RTSM, CTMS and eTMF, plus a documented pattern for the sponsor-mandated modules that will still arrive [1][2][3]. A shared core can support reusable platform validation evidence, but connected services and intended uses may still need separate evidence; the per-study validation of protocol-specific configuration remains, as does a sponsor-facing system description and data-flow diagram for every study, which is the artefact EMA section 5.1 and FDA question 8 describe.

Methodology and limitations

Takeaway: Five independent lanes: the registry cohort, an NIH research corpus, two FDA inspection files, primary regulatory and standards documents, and the literature. Each has a stated boundary.

Lane A is an analysis of 18,064 interventional trials with an industry lead sponsor, phase 1, 1/2 or 2, and a start date from 2021 to 2026, in the ClinicalTrials.gov record downloaded 25 July 2026 and read through the AACT copy of 1 August 2026 [1][5]. Module flags come from the allocation and masking fields, the registered facility and country counts, and fixed term lists applied to outcome measures, descriptions and summaries; the four counted modules are randomisation or masking, patient-reported terms, explicit central-review language and two or more facilities. Small sponsors are lead sponsors with three or fewer registered studies, tested against four alternative proxies.

Lane B is a 31-phrase NIH RePORTER corpus of 4,876 unique project applications, themed by fixed term lists on title, abstract and terms [28]. Lane C is two FDA files: 2,264 Bioresearch Monitoring rows of Form FDA 483 citation frequency sums for FY2006 to FY2025, and the full text of the 69 warning letters with clinical-trial subjects among 3,643 letters issued from 2021 to July 2026 [7][8]. Lane D is the primary documents from ICH, EMA, FDA, CDISC and TransCelerate, quoted from the published texts [2][3][4][14][15][17][18][19][20]. Lane E is live Europe PMC counts and seven papers read in abstract [21][22][24][25][26][6][27][23].

The boundaries [1][7][28]: registry fields and text flags are unvalidated capability indicators, with possible false positives and omissions. They are not lower bounds on software need or a record of purchases. A point for multiple sites is built into the score, so the site-count association is partly definitional. The cohort is not restricted to first-ever trials and phase labels limit its relevance to phase-NA device studies; facility counts are the registered number at snapshot; 2026 starts are partly estimated; the sponsor proxy measures registry footprint; citation frequency sums have no inspection denominator and workbook schemas differ by year; the warning-letter selection is by subject and regex; NIH awards are research themes; the EHR-to-EDC papers are single-network evaluations and the error-rate meta-analysis pools papers from 1978 to 2008; and no neutral third-party evidence on suite-versus-point-solution outcomes was found, which is why the sourcing path reasons from obligations rather than from outcomes.

Conclusion

Takeaway: Three conclusions carry the decision.

First, scope from the protocol, not the company. Data capture and essential-record management are baseline functions; 49.5% of early-phase industry records have one capability signal on top of it, and the score differs by phase and site band while remaining descriptively similar across registry-footprint groups. Headcount effects and product counts require different evidence.

Second, the obligations travel with the sponsor on every sourcing path. ICH E6(R3), the EMA guideline and the FDA guidance ask for a system inventory with interfaces, a data-flow diagram, validated trial-specific configuration and transfers, and documented oversight of service providers, whether the stack is one platform, five or the CRO's.

Third, choose the sourcing model by where you want the seams. The inspection record describes failures at the interfaces between systems, transcription steps and vendors. An integrated platform such as EClinCloud’s may reduce some cross-vendor interfaces, subject to its actual architecture and study scope; a best-of-breed set keeps specialist modules at the cost of more seams; a CRO-supplied stack moves the seam into the contract and the export. In every case, define the interfaces, validate the transfers and keep access to the records and their audit trails.

The module map and the sourcing decision path above are built to be run against a synopsis before the first vendor call; a study-build or data-management team, EClinCloud's included, can take a synopsis through them and return the system list, data-flow diagram and open questions the guidance asks for.

Sources

1. U.S. National Library of Medicine, ClinicalTrials.gov, read through the CTTI AACT database (aact.ctti-clinicaltrials.org), accessed September 2026. EClinCloud analysis of the 25 July 2026 registry download (AACT copy 1 August 2026): 18,064 interventional trials with an industry lead sponsor, phase 1, 1/2 or 2, started 2021 to 2026; module flags from allocation, masking, outcome text, summaries, facility and country counts; unvalidated text indicators.

2. International Council for Harmonisation, ICH E6(R3) Guideline for Good Clinical Practice, accessed September 2026. Principles and Annex 1 adopted 6 January 2025; Annex 2 adopted 3 June 2026; consolidated guideline dated 16 June 2026. Quoted sections 3.6, 3.9.5, 3.16.1, 4.2.1, 4.2.5, 4.2.6, 4.3.4 and Principle 9.3.

3. European Medicines Agency, GCP Inspectors Working Group, Guideline on computerised systems and electronic data in clinical trials, EMA/INS/GCP/112288/2023, accessed September 2026. Adopted 7 March 2023, in effect six months after publication; quoted sections 2, 4.2, 4.3, 4.10, 5.1 and 6.1.2.

4. U.S. Food and Drug Administration, Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers, Guidance for Industry, accessed September 2026. October 2024, Revision 1; nonbinding recommendations; quoted section B, Q7, Q8 and section C.

5. U.S. National Library of Medicine, ClinicalTrials.gov Protocol Registration Data Element Definitions, accessed September 2026. Definitions of Allocation (Randomized, Nonrandomized), Masking, Number of Arms and the Phase 1, Phase 1/Phase 2 and Phase 2 categories used to build the cohort.

6. Contu S, Schiappa R, Chateau Y, Chamorey E, Automatic tool for the reconciliation of serious adverse events for pharmacovigilance: design and implementation of Reconciliaid, Ther Adv Drug Saf, 2025, PMID 39830586, accessed September 2026. 13 reconciliation files, 290 serious adverse events.

7. U.S. Food and Drug Administration, Inspection Observations (Form FDA 483 citation frequency workbooks, FY2006 to FY2025), accessed September 2026. EClinCloud analysis of the 2,264 Bioresearch Monitoring rows; frequency sums by fiscal year and citation, not rates.

8. U.S. Food and Drug Administration, Warning Letters, accessed September 2026. EClinCloud analysis of the 3,643 letters issued 2021 to July 2026; full-text scan of the 69 letters with clinical-investigator, sponsor, BIMO, IRB or bioequivalence subjects.

9. U.S. Food and Drug Administration, Warning Letter to Adnan Dahdul, MD, 12 March 2026, accessed September 2026. Clinical Investigator/BIMO; source data not matching the EDC and nonattributable entries.

10. U.S. Food and Drug Administration, Warning Letter to Amy Lightner, MD, 25 March 2025, accessed September 2026. Bioresearch Monitoring Program; investigational-product supplier closed its EDC system.

11. U.S. Food and Drug Administration, Warning Letter to Applied Therapeutics, Inc., 3 December 2024, accessed September 2026. Sponsor; third-party vendor deleted electronic data and audit trails.

12. U.S. Food and Drug Administration, Warning Letter to Namita A. Goyal, M.D., 10 October 2024, accessed September 2026. Clinical Investigator; discrepancies between sponsor forms, progress notes and EDC.

13. U.S. Food and Drug Administration, Warning Letter to Kevin R. Bender, M.D./DBC Research Corporation, 2 May 2024, accessed September 2026. Clinical Investigator; kit reconciliation between site records and the IWRS.

14. U.S. Food and Drug Administration, Electronic Source Data in Clinical Investigations, Guidance for Industry, accessed September 2026. September 2013; direct entry into the eCRF and the aim of eliminating unnecessary duplication of data.

15. U.S. Food and Drug Administration, Providing Regulatory Submissions in Electronic Format: Standardized Study Data, Guidance for Industry, accessed September 2026. Revision 2, June 2021; requirement dates 18 December 2016 (NDA, ANDA, certain BLA) and 18 December 2017 (certain IND); conformance on dm.xpt, adsl.xpt and define.xml.

16. U.S. Food and Drug Administration, Study Data Standards Resources (including the FDA Data Standards Catalog), accessed September 2026. Page current as of 17 June 2026; Catalog, Technical Rejection Criteria and Conformance Guide.

17. CDISC, Operational Data Model (ODM) and ODM v2.0, accessed September 2026. Vendor-neutral, platform-independent exchange and archival format for clinical study data with metadata, administrative data and audit information; v2.0 adds a REST API specification and JSON.

18. CDISC, Define-XML, accessed September 2026. Dataset metadata standard required by FDA and PMDA for every study in each electronic submission; v2.1.11 released 6 April 2026.

19. CDISC, TMF Reference Model (TMF Standard Model), accessed September 2026. Standard taxonomy and metadata for trial master file content; part of CDISC since June 2022; version 3.3.1.

20. TransCelerate BioPharma, eSource Solutions, accessed September 2026. Initiative begun in 2016 and completed; FHIR-to-SDTM mapping for labs, adverse events and schedule of activities; continued work through the HL7 Vulcan FHIR Accelerator.

21. Garza MY, Williams T, Ounpraseuth S, et al., Error rates of data processing methods in clinical research: a systematic review and meta-analysis of manuscripts identified through PubMed, Int J Med Inform, 2025, PMID 39647291, accessed September 2026. 93 papers published 1978 to 2008; pooled error rates by data processing method.

22. Williamson J, Jalkanen J, Lahtinen M, Small pharma vendor management practices in clinical trials: a case study within Faron Pharmaceuticals, Drug Discov Today, 2023, PMID 36921669, accessed September 2026. Single-company case study of vendor selection, oversight and evaluation.

23. Europe PMC, accessed September 2026. EClinCloud analysis: live REST API hit counts by publication year for six fixed queries; counts are not prevalence.

24. Ammour N, Griffon N, Djadi-Prat J, et al., TransFAIR study: a European multicentre experimental comparison of EHR2EDC technology to the usual manual method for eCRF data collection, BMJ Health Care Inform, 2023, PMID 37316249, accessed September 2026. Six trials, three sponsors, three hospitals; 6,143 data points transferred.

25. Pfeffer M, Deneris M, Shelley A, Salcuni P, Altomare I, Utility of automated data transfer for cancer clinical trials and considerations for implementation, ESMO Real World Data Digit Oncol, 2025, PMID 41647346, accessed September 2026. Multiple phase I cancer trials; 11,342 data points over 15 months.

26. Cheng AC, Banasiewicz MK, Gibbs KW, et al., Multisite evaluation of automated electronic case report form data entry from electronic health records, J Biomed Inform, 2026, PMID 42217712, accessed September 2026. Set-up hours at two receiving sites; errors prevented and time saved for 20 participants.

27. Eisenstein EL, Zozus MN, Garza MY, et al., Assessing clinical site readiness for electronic health record (EHR)-to-electronic data capture (EDC) automated data collection, Contemp Clin Trials, 2023, PMID 36898625, accessed September 2026. Survey of 61 respondents at Pediatric Trials Network sites.

28. U.S. National Institutes of Health, NIH RePORTER, accessed September 2026. EClinCloud analysis of a 31-phrase eClinical corpus of 4,876 unique project applications (snapshot 23 August 2026); research themes, not adoption evidence.

29. EClinCloud, EDC: Electronic Data Capture, accessed September 2026. Product scope; native connections to RTSM, eCOA and CTMS with integration scope confirmed during evaluation.

30. EClinCloud, RTSM: Randomization and Trial Supply Management, accessed September 2026. Product scope; randomisation and dispensing data shared with EDC on one platform.

31. EClinCloud, Professional Services, accessed September 2026. Study build and configuration, data and BI, implementation and managed services; service scope only.